Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
In the setting of conventional radiation therapy, even when combined with immunotherapy, head and neck cancer often recurs locally and regionally. Elective nodal irradiation (ENI) is commonly employed to decrease regional recurrence. Given our developing understanding that immune cells are radio-sensitive, and that T cell priming occurs in the draining lymph nodes (DLNs), we hypothesize that radiation therapy directed at the primary tumor only will increase the effectiveness of immunotherapies. We find that ENI increases local, distant, and metastatic tumor growth. Multi-compartmental analysis of the primary/distant tumor, the DLNs, and the blood shows that ENI decreases the immune response systemically. Additionally, we find that ENI decreases antigen-specific T cells and epitope spreading. Treating the primary tumor with radiation and immunotherapy, however, fails to reduce regional recurrence, but this is reversed by either concurrent sentinel lymph node resection or irradiation. Our data support using lymphatic sparing radiation therapy for head and neck cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hiam-Galvez, K. J., Allen, B. M., & Spitzer, M. H. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00347-z · Cited by 1,400
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Löwer, M., Diekmann, J., Boegel, S., Schrörs, B., Vascotto, F., Castle, J. C., et al. (2015) · Nature · doi:10.1038/nature14426 · Cited by 1,243 · cited 2×
“MHC II binding antigens, which are presented only to CD4 T cells, were also recently used to vaccinate patients against cancer 41 .”
Systemic Immunity Is Required for Effective Cancer Immunotherapy
Spitzer, M. H., Carmi, Y., Reticker-Flynn, N. E., Kwek, S. S., Madhireddy, D., Martins, M. M., Gherardini, P. F., Prestwood, T. R., Chabon, J., Bendall, S. C., et al. (2017) · Cell · doi:10.1016/j.cell.2016.12.022 · Cited by 963 · cited 1×
“When in circulation, this CD4 Th1 signature population has been shown to correlate with response to immunotherapy 21 .”
MHC-II neoantigens shape tumour immunity and response to immunotherapy
Alspach, E., Lussier, D. M., Miceli, A. P., Kizhvatov, I., DuPage, M., Luoma, A. M., Meng, W., Lichti, C. F., Esaulova, E., Vomund, A. N., et al. (2019) · Nature · doi:10.1038/s41586-019-1671-8 · Cited by 846 · cited 1×
“However, it has been shown that antigen-mediated activation of both CD8 T cells and CD4 T cells is indispensable for a robust anti-tumor immune response 36,40 .”
Lee, N. Y., Ferris, R. L., Psyrri, A., Haddad, R. I., Tahara, M., Bourhis, J., Harrington, K., Chang, P. M.-H., Lin, J.-C., Razaq, M. A., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30737-3 · Cited by 661
Primary Antitumor Immune Response Mediated by CD4+ T Cells
Corthay, A., Skovseth, D. K., Lundin, K. U., Røsjø, E., Omholt, H., Hofgaard, P. O., Haraldsen, G., & Bogen, B. (2005) · Immunity · doi:10.1016/j.immuni.2005.02.003 · Cited by 478 · cited 1×
“CD4 T cells are classically known as supporting cells that maintain the immune response and support CD8 T cell-mediated cell kill by providing survival signals like IL-2 37 – 39 .”
McBride, S., Sherman, E., Tsai, C. J., Baxi, S., Aghalar, J., Eng, J., Zhi, W. I., McFarland, D., Michel, L. S., Young, R., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.00290 · Cited by 402 · cited 1×
“modestatbest 5 .”
Cited by
Emerging evidence for adapting radiotherapy to immunotherapy
Galluzzi, L., Aryankalayil, M. J., Coleman, C. N., & Formenti, S. C. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00782-x · Cited by 368
Metadata
- Authors
- Darragh, L. B., Gadwa, J., Pham, T. T., Van Court, B., Neupert, B., Olimpo, N. A., Nguyen, K., Nguyen, D., Knitz, M. W., Hoen, M., Corbo, S., Joshi, M., Zhuang, Y., Amann, M., Wang, X.-J., Dow, S., Kedl, R. M., Samedi, V., Boss, M.-K., & Karam, S. D.
- Venue
- Nature Communications
- Published
- 2022-11-16
- Volume
- 13
- Issue
- 1
- Pages
- 7015-7015
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W4309475449
- Cited by
- 235
- References
- 7
- FWCI
- 33.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors. https://app.cochat.ai/papers/10.1038/s41467-022-34676-w
- The paper
- Darragh, L. B., Gadwa, J., Pham, T. T., Van Court, B., Neupert, B., Olimpo, N. A., Nguyen, K., Nguyen, D., Knitz, M. W., Hoen, M., Corbo, S., Joshi, M., Zhuang, Y., Amann, M., Wang, X.-J., Dow, S., Kedl, R. M., Samedi, V., Boss, M.-K., & Karam, S. D. (2022). Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors. Nature Communications. https://doi.org/10.1038/s41467-022-34676-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.